4-(4-甲氧基苯基)嘧啶-2-硫醇 | 175202-77-4

• 物质功能分类: 化学试剂 - 有机试剂 - 硫醇盐
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-(4-甲氧基苯基)嘧啶-2-硫醇
• 英文名称: 4-(4-methoxyphenyl)pyrimidine-2-thiol
• 英文别名: 6-(4-methoxyphenyl)-1H-pyrimidine-2-thione
• CAS: 175202-77-4
• 化学式: C₁₁H₁₀N₂OS
• mdl: MFCD00085109
• 分子量: 218.279
• InChiKey: KSXDNCUHISGCTF-UHFFFAOYSA-N

物化性质

• 熔点：
  202 °C
• 沸点：
  368.0±52.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  65.7
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 海关编码：
  2933599090
• 危险性防范说明：
  P501,P270,P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313,P301+P312+P330
• 危险性描述：
  H302,H315,H319

SDS

Name:	4-(4-Methoxyphenyl)pyrimidine-2-thiol 95+% Material Safety Data Sheet
Synonym:
CAS:	175202-77-4

Section 1 - Chemical Product MSDS Name:4-(4-Methoxyphenyl)pyrimidine-2-thiol 95+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
175202-77-4	4-(4-Methoxyphenyl)pyrimidine-2-thiol	95+%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 175202-77-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 192 - 202 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H10N2OS
Molecular Weight: 218

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen cyanide, nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 175202-77-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-(4-Methoxyphenyl)pyrimidine-2-thiol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 175202-77-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 175202-77-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 175202-77-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(4-甲氧基苯基)嘧啶-2-硫醇 在 potassium carbonate 、 一水合肼 作用下， 以 乙醇 、 丙酮 为溶剂， 反应 25.0h， 生成 N'-(4-(pyrrolidin-1-yl)benzylidene)-2-[(4-(4-methoxyphenyl)pyrimidin-2-yl)thio]acetohydrazide
  参考文献：
  名称：

  Design, Synthesis, In vitro and In silico Evaluation of New Hydrazonebased Antitumor Agents as Potent Akt Inhibitors

  摘要：

  背景：Akt在多种人类癌症中过度表达或激活，包括胶质瘤、肺癌、乳腺癌、卵巢癌、胃癌和胰腺癌。Akt抑制导致细胞凋亡和肿瘤生长受到抑制，因此大量的工作致力于发现针对Akt的有效抗肿瘤药物。 目的：本研究的目的是鉴定针对Akt的有效抗癌剂。 方法：合成了新的腙类衍生物，并研究了它们对5RP7 H-ras致癌基因转化的大鼠胚胎成纤维细胞和L929小鼠胚胎成纤维细胞株的细胞毒性作用。此外，还使用流式细胞术评估了最活跃化合物对5RP7细胞株的凋亡作用。使用比色法研究了它们对Akt的抑制作用。还使用Schrödinger的Maestro分子建模软件进行了计算机模拟对接和吸收、分布、代谢和排泄（ADME）研究。 结果和讨论：化合物3a、3d、3g和3j在5RP7细胞上表现出良好的效果（IC50值分别为<0.97、<0.97、1.13±0.06和<0.97μg/mL），与顺铂（IC50=1.87±0.15μg/mL）相比。这四个化合物被确定为能够显著诱导5RP7细胞株的凋亡。其中，N'-苄基亚甲基-2-[(4-（4-甲氧基苯基）嘧啶-2-基）硫]乙酰肼（3g）在抑制Akt方面表现出显著的效果（IC50=0.5±0.08μg/mL），与GSK690693（IC50=0.6±0.05μg/mL）相比。对接研究表明，化合物3g与Akt的活性位点（PDB代码：2JDO）具有良好的亲和力。根据计算机模拟的ADME研究，该化合物也符合Lipinski的五项规则和Jorgensen的三项规则。 结论：化合物3g是一种潜在的口服可用的针对Akt的细胞毒性剂和凋亡诱导剂。

  DOI：

  10.2174/1570180817999200618163507

文献信息

• Nanoscale synthesis and affinity ranking
  作者：Nathan J. Gesmundo、Bérengère Sauvagnat、Patrick J. Curran、Matthew P. Richards、Christine L. Andrews、Peter J. Dandliker、Tim Cernak

  DOI：10.1038/s41586-018-0056-8

  日期：2018.5

  Most drugs are developed through iterative rounds of chemical synthesis and biochemical testing to optimize the affinity of a particular compound for a protein target of therapeutic interest. This process is challenging because candidate molecules must be selected from a chemical space of more than 1060 drug-like possibilities 1 , and a single reaction used to synthesize each molecule has more than 107 plausible permutations of catalysts, ligands, additives and other parameters 2 . The merger of a method for high-throughput chemical synthesis with a biochemical assay would facilitate the exploration of this enormous search space and streamline the hunt for new drugs and chemical probes. Miniaturized high-throughput chemical synthesis3–7 has enabled rapid evaluation of reaction space, but so far the merger of such syntheses with bioassays has been achieved with only low-density reaction arrays, which analyse only a handful of analogues prepared under a single reaction condition8–13. High-density chemical synthesis approaches that have been coupled to bioassays, including on-bead 14 , on-surface 15 , on-DNA 16 and mass-encoding technologies 17 , greatly reduce material requirements, but they require the covalent linkage of substrates to a potentially reactive support, must be performed under high dilution and must operate in a mixture format. These reaction attributes limit the application of transition-metal catalysts, which are easily poisoned by the many functional groups present in a complex mixture, and of transformations for which the kinetics require a high concentration of reactant. Here we couple high-throughput nanomole-scale synthesis with a label-free affinity-selection mass spectrometry bioassay. Each reaction is performed at a 0.1-molar concentration in a discrete well to enable transition-metal catalysis while consuming less than 0.05 milligrams of substrate per reaction. The affinity-selection mass spectrometry bioassay is then used to rank the affinity of the reaction products to target proteins, removing the need for time-intensive reaction purification. This method enables the primary synthesis and testing steps that are critical to the invention of protein inhibitors to be performed rapidly and with minimal consumption of starting materials. A system that combines nanoscale synthesis and affinity ranking enables high-throughput screening of reaction conditions and bioactivity for a given protein target, accelerating the process of drug discovery.

  大多数药物都是通过反复的化学合成和生化测试来开发，以优化特定化合物与治疗感兴趣的蛋白质靶点的亲和力。这一过程颇具挑战性，因为候选分子必须从超过10^60种类药物可能性的化学空间中选出，而用于合成每个分子的单一反应中催化剂、配体、添加剂和其他参数的合理排列组合超过10^7种。将高通量化学合成方法与生化分析方法相结合，将有助于探索这一巨大的搜索空间，并简化新型药物和化学探针的寻找过程。微型化高通量化学合成技术已经能够快速评估反应空间，但迄今为止，这种合成方法与生物分析方法的结合，仅限于低密度反应阵列，即在单一反应条件下仅分析少量类似物。高密度化学合成方法与生物分析方法相结合，包括使用珠子上、表面上、DNA上和质量编码等技术，大大减少了材料需求，但这些方法要求底物与潜在的反应性载体共价连接，必须在高度稀释的情况下进行，并且必须在混合物的形式下运作。这些反应特性限制了过渡金属催化剂的应用，因为过渡金属催化剂很容易受到复杂混合物中存在的多种官能团的毒害，而且对于动力学需要高浓度反应物的反应过程也不适用。本研究将高通量纳摩尔级合成与无标记的亲和选择质谱生物分析相结合，使得每个反应在0.1摩尔浓度的条件下进行，既可能实现过渡金属催化，又使得每个反应消耗的底物不足0.05毫克。然后，使用亲和选择质谱生物分析法对反应产物与靶蛋白的亲和力进行排序，省去了耗时的反应纯化步骤。该方法使得对蛋白质抑制剂发明至关重要的初级合成和测试步骤能够快速完成，且起始材料消耗最小。纳米级合成和亲和力排序相结合的系统可以实现对给定蛋白质靶点的反应条件和生物活性进行高通量筛选，从而加速药物发现过程。
• [EN] INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] INHIBITEURS D'HISTONE DÉSACÉTYLASE
  申请人：METHYLGENE INC

  公开号：WO2005092899A1

  公开（公告）日：2005-10-06

  The invention relates to a series of compounds useful for inhibiting histone deacetylase (HDAC) enzymatic activity. The invention also provides a method for inhibiting histone descetylase in a cell using said compounds as well as a method for treating cell proliferative diseases and conditions using said HDAC inhibitors. Further, the invention provides pharmaceutical compositions comprising the HDAC inhibiting compounds and a pharmaceutically acceptable carrier.

  这项发明涉及一系列对抑制组蛋白去乙酰化酶（HDAC）酶活性有用的化合物。该发明还提供了一种利用这些化合物抑制细胞中组蛋白去乙酰化酶的方法，以及一种利用这些HDAC抑制剂治疗细胞增殖性疾病和病况的方法。此外，该发明提供了包含这些HDAC抑制化合物和药用可接受载体的药物组合物。
• Oxazolidinone combinatorial libraries, compositions and methods of preparation
  申请人：Gordeev F. Mikhail

  公开号：US20050004174A1

  公开（公告）日：2005-01-06

  Oxazolidinones and methods for their synthesis are provided. Also provided are combinatorial libraries comprising oxazolidinones, and methods to prepare the libraries. Further provided are methods of making biologically active oxazolidinones as well as pharmaceutically acceptable compositions comprising the oxazolidinones. The methods of library preparation include the attachment of oxazolidinones to a solid support. The methods of compound preparation in one embodiment involve the reaction of an iminophosphorane with a carbonyl containing polymeric support.

  本发明提供了氧杂环丙烷酮及其合成方法。还提供了包含氧杂环丙烷酮的组合化学文库以及制备这些文库的方法。此外，还提供了制备生物活性氧杂环丙烷酮的方法以及包含氧杂环丙烷酮的药学可接受组合物的方法。文库制备的方法包括将氧杂环丙烷酮附着到固体支持上。在一种实施例中，化合物制备的方法涉及将亚胺磷酰胺与含有羰基的聚合物支持物反应。
• Inhibitors of Histone Deacetylase
  申请人：Delorme Daniel

  公开号：US20070213330A1

  公开（公告）日：2007-09-13

  The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  本发明涉及抑制组蛋白去乙酰化酶的技术。本发明提供了抑制组蛋白去乙酰化酶酶活性的化合物和方法。本发明还提供了治疗细胞增殖性疾病和病况的组合物和方法。
• Inhibitors of histone deacetylase
  申请人：MethylGene Inc.

  公开号：US08088805B2

  公开（公告）日：2012-01-03

  The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  本发明涉及抑制组蛋白去乙酰化酶。本发明提供了抑制组蛋白去乙酰化酶酶活性的化合物和方法。本发明还提供了治疗细胞增殖性疾病和病症的组合物和方法。